Key Highlights

  • 26.39% of the float in Tango Therapeutics (NASDAQ:TNGX) is sold short with 12.5 days to cover, per published market data on October 16, 2026 intraday. FINRA data for September 30, 2026 shows 44.5 million shares short, up from 41.9 million on September 15.
  • USD 22.66 was the intraday price on October 16, 2026, down 0.20%, and 21.9% below the USD 29.00 close on August 6, 2026 (own arithmetic). No company-specific catalyst was identified for the session; the FDA approved Revolution Medicines (NASDAQ:RVMD) daraxonrasib on August 26, 2026.
  • 92% objective response rate (11 of 12 response-evaluable patients) was reported on June 8, 2026 for vopimetostat plus daraxonrasib in pancreatic cancer, with a 90% six-month progression-free survival rate. Updated data are due at ESMO, October 23 to 27, 2026.
  • USD 1.0 billion of cash and securities at June 30, 2026 equals 26% of the USD 3.82 billion table market capitalisation (own arithmetic). The second quarter net loss was USD 55.3 million, per the August 11, 2026 results.

Price Action and Short Positioning

One share in four is sold short ahead of a binary data event. Days to cover is shares short divided by average daily volume, and 12.5 implies average volume of 3.56 million shares (own arithmetic). At USD 22.66 the short position is worth USD 1.01 billion (own arithmetic), equal to the company cash balance. Short interest peaked at 48.7 million shares on February 27, 2026. Piper Sandler (NYSE:PIPR) cut Tango to Neutral on May 15, 2026, raising its target to USD 24. Published market data on August 7 showed an average target of USD 42.15, 86% above the current price (own arithmetic).

Clinical Thesis and Competitive Overlap

The June 8, 2026 release covered 59 patients on vopimetostat, a PRMT5 inhibitor, with RAS(ON) inhibitors. Daraxonrasib produced responses in 11 of 12 evaluable pancreatic patients; zoldonrasib produced a 52% response rate in 27, with a 74% six-month progression-free survival rate. The shorts' rationale is not disclosed; supportable concerns are small samples, which the release says may not replicate, and dependence on a partner drug. Daraxonrasib won FDA approval on August 26, 2026 as a second-line monotherapy, with median overall survival of 13.2 months against 6.7 months for chemotherapy in the 500-patient RASolute 302 trial.

Balance Sheet, Catalysts and Risks

Cash is a cushion. USD 1.0 billion covers 4.5 years at the second quarter net loss annualised to USD 221 million (own arithmetic), before Phase 3 costs. The company is finalising a randomised Phase 3 design in first-line pancreatic cancer and has not announced an offering. Catalysts are the ESMO presentation, lung cancer monotherapy data and initial TNG456 glioblastoma data, all guided for the second half of 2026. Strong data could force covering; weak data would validate the shorts. The third quarter results date is not confirmed.

Where Things Stand

A squeeze is possible, but it depends on the ESMO data rather than on any signal visible today. Tango Therapeutics (NASDAQ:TNGX) carries 26.39% short interest and 12.5 days to cover, a combination that amplifies moves in either direction, and shares slipped 0.20% intraday on October 16, 2026 with no catalyst. Cash of USD 1.0 billion and a 92% response rate in a small cohort support the bulls. Small samples, partner dependence and Phase 3 cost support the shorts. The next dated catalyst is ESMO, October 23 to 27, 2026.